SCHEMBL2273832

SCHEMBL2273832

O=C(Nc1cc(N2CCc3ccccc3C2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 7/20 0.54
PPARD Q03181 7/20 0.54
PPARA Q07869 6/20 0.54
MEN1 O00255 3/20 0.51
PKM P14618 3/20 0.51
KMT2A Q03164 3/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
MAPT P10636 2/20 0.50
GRIK1 P39086 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HTT P42858 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
PLA2G1B P04054 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
SERPINE1 P05121 1/20 0.43
HDAC1 Q13547 1/20 0.43
PDGFRB P09619 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269025 0.81 MAPT (0.50) PPARGPPARDPPARAMEN1PKM
SCHEMBL2268310 0.80 MAPT (0.48) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL4212896 0.79 MEN1 (0.48) PPARGPPARDPPARAMEN1PKM
SCHEMBL2270309 0.77 PKM (0.50) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL2275234 0.77 MALT1 (0.51) MEN1PKMKMT2AALDH1A1HPGD
SCHEMBL2273168 0.75 SERPINE1 (0.61) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL2276799 0.74 MALT1 (0.52) MEN1PKMKMT2AMAPTGRIK1
SCHEMBL16061897 0.74 MEN1 (0.57) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL30109424 0.74 MEN1 (0.57) MEN1PKMKMT2AKDM4EALDH1A1
SCHEMBL28457712 0.73 ALDH1A1 (0.61) MEN1PKMKMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 PPARG 2066/4885PPARD 3684/4885PPARA 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.